GUIDO CIPRANDI

Prof. Dr. GUIDO CIPRANDI

orcid

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
28 October 2023 in Burns
Verified
Journal Article
Open access
BBBouke K.H.L. Boekema
Bouke K.H.L. Boekema
DCDaniela Chrysostomou
Daniela Chrysostomou
GUIDO CIPRANDIGUIDO CIPRANDI
GUIDO CIPRANDI
AEAnouk Elgersma
Anouk Elgersma
MVMarcel Vlig
Marcel Vlig
Niels CremersNiels Cremers
Niels Cremers
Burns are a major global healthcare concern, often complicated by the presence of bacteria such as Pseudomonas aeruginosa in the wounds. Silver-based dressings are commonly used in the treatment of burns but can cause skin irritation and delay healing time. Medical-grade honey (MGH) provides an interesting alternative. This study investigated the antimicrobial effects and possible cytotoxicity of L-Mesitran Soft (MGH-gel) and its individual components, Medihoney (Manuka), Flammazine (silver sulphadiazine), and silver nitrate (AgNO3) in an ex vivo human burn wound model. Bacterial survival and wound healing parameters, including re-epithelialization and keratinocyte proliferation were assessed. L-Mesitran, Flammazine, and AgNO3 reduced P. aeruginosa numbers below detection levels. L-Mesitran Soft exhibited a significantly stronger antimicrobial effect compared to Medihoney. The individual components of L-Mesitran contributed significantly to its antibacterial efficacy, thus suggesting synergistic activities. Moreover, L-Mesitran, Flammazine, and AgNO3 slightly inhibited re-epithelialization while Medihoney treatment resulted in a complete lack of re-epithelialization and keratinocyte proliferation. Furthermore, clinical cases illustrated the effectiveness of MGH therapy in infected burns. Overall, L-Mesitran Soft had similar effects as silver-based products on bacterial load and epidermal regeneration, but outperformed Medihoney. Therefore, supplemented MGH could be used as an effective alternative to silver-based dressings for P. aeruginosa-infected burns.

17 October 2022 in International Wound Journal
Verified
Journal Article
Open access
GUIDO CIPRANDIGUIDO CIPRANDI
GUIDO CIPRANDI
SCSerena Crucianelli
Serena Crucianelli
MZMario Zama
Mario Zama
GAGiancarlo Antonielli
Giancarlo Antonielli
RARiccarda Armani
Riccarda Armani
NSNick Santamaria
Nick Santamaria
The prevention of hospital‐acquired pressure injuries (HAPIs) in children undergoing long‐duration surgical procedures is of critical importance due to the potential for catastrophic sequelae of these generally preventable injuries for the child and their family. Long‐duration surgical procedures in children have the potential to result in high rates of HAPI due to physiological factors and the difficulty or impossibility of repositioning these patients intraoperatively. We developed and implemented a multi‐modal, multi‐disciplinary translational HAPI prevention quality improvement program at a large European Paediatric University Teaching Hospital. The intervention comprised the establishment of wound prevention teams, modified HAPI risk assessment tools, specific education, and the use of prophylactic dressings and fluidized positioners during long‐duration surgical procedures. As part of the evaluation of the effectiveness of the program in reducing intraoperative HAPI, we conducted a prospective cohort study of 200 children undergoing long‐duration surgical procedures and compared their outcomes with a matched historical cohort of 200 children who had undergone similar surgery the previous year. The findings demonstrated a reduction in HAPI in the intervention cohort of 80% (p < 0.01) compared to the comparator group when controlling for age, pathology, comorbidity, and surgical duration. We believe that the findings demonstrate that it is possible to significantly decrease HAPI incidence in these highly vulnerable children by using an evidence‐based, multi‐modal, multidisciplinary HAPI prevention strategy.

1 November 2018 in Journal of Tissue Viability
Verified
Journal Article
Closed access
GUIDO CIPRANDIGUIDO CIPRANDI
GUIDO CIPRANDI
SRSharon Ramsay
Sharon Ramsay
LBLudmilla Budkevich
Ludmilla Budkevich
ASAndreas Strack
Andreas Strack
PCPetra van Capellen
Petra van Capellen
NMNicos Marathovouniotis
Nicos Marathovouniotis

1 November 2022 in Chronic Wound Care Management and Research
Verified
Journal Article
Open access
PDF file
GUIDO CIPRANDIGUIDO CIPRANDI
GUIDO CIPRANDI
SCSerena Crucianelli
Serena Crucianelli
FGFrancesca Grussu
Francesca Grussu
GSGiorgio Spuntarelli
Giorgio Spuntarelli
SMSimone Faustino Maria Marino
Simone Faustino Maria Marino
MZMario Zama
Mario Zama
Although similar in structure, pediatric skin is more delicate and vulnerable compared with adult skin and, as a result, is more prone to wounding. The immune response in pediatric skin is underdeveloped because of immature inflammatory cells and lower number of bone marrow progenitor cells. Therefore, pediatric patients, particularly newborns, have weak responses to microorganisms. The use of antimicrobial agents (eg, antibiotics, antimicrobial wound dressings, etc.) to aid in the prevention and/or treatment of wounds prone to or which are infected is one treatment option. Antimicrobial wound dressings using DACC technology physically bind bacteria and reduce the need for chemically active antimicrobial agents. This perspective is intended to highlight the benefit of DACC technology wound dressings for the prevention and treatment of pediatric wounds related to wound infection. We have found that DACC technology dressings are of benefit in the treatment of pediatric wounds and offer a significant resource for the treatment of pediatric wounds.

Verified
Journal Article
Open access
PDF file
RFRiccardo Foti
Riccardo Foti
Gabriele StortiGabriele Storti
Gabriele Storti
MPMarco Palmesano
Marco Palmesano
ACAlessio Calicchia
Alessio Calicchia
RFRoberta Foti
Roberta Foti
VCVALERIO CERVELLI
VALERIO CERVELLI
Artificial intelligence (AI), including machine learning (ML) and deep learning (DL), is increasingly transforming the study, manufacturing, and clinical translation of adipose-derived stem/stromal cells (ADSCs). ADSC-based therapies face persistent challenges related to donor variability, heterogeneous cell populations, limited standardization of culture protocols, and the need for robust quality control (QC) and potency assessment under Good Manufacturing Practice (GMP) conditions. This review discusses how AI-driven approaches can support the ADSC pipeline from donor and tissue pre-screening, through isolation and expansion, to differentiation and batch release decisions. We highlight major methodological advances in computer vision and label-free imaging for monitoring morphology, confluency, proliferation, senescence, and contamination, as well as AI-assisted optimization strategies for culture parameters and differentiation protocols. In addition, we examine the growing role of multi-omics integration (transcriptomics, proteomics, metabolomics, and secretomics) combined with ML to predict functional potency, stratify donors, and identify biomarkers associated with therapeutic efficacy. Finally, we address current limitations, including data scarcity, inter-laboratory variability, model interpretability, and regulatory requirements, and outline future perspectives such as closed-loop bioprocess control, foundation models, and federated learning frameworks. Overall, AI offers a powerful toolkit to improve the reproducibility, safety, and scalability of ADSC manufacturing and to accelerate the development of standardized, data-driven regenerative medicine products.

19 June 2025 in Children
Verified
Journal Article
Open access
PDF file
Biagio NicolosiBiagio Nicolosi
Biagio Nicolosi
EBEleonora Bastarelli
Eleonora Bastarelli
MGMirco Gregorini
Mirco Gregorini
GUIDO CIPRANDIGUIDO CIPRANDI
GUIDO CIPRANDI
Background/Objectives: Pediatric skin injuries represent a clinical challenge, especially in cases with complex etiology or with severe pain. Blue light is an emerging technology with potential application in pediatric wound care. The aim of this case series was to describe the clinical use of blue light in pediatric patients with injuries of varying etiologies and mechanisms, and to assess its long-term effectiveness and sustainability in treatment. Methods: Twelve hospitalized pediatric patients (0–12 years old) with skin injuries were included in this case series. The etiologies of wounds treated with photobiomodulation were incontinence-associated dermatitis, peristomal injuries, and pressure injuries. The injuries were assessed using specific classification tools and pain scales. The wounds were treated every three days using a medical device that emits blue light (410–430 nm). When necessary, wounds were also treated with appropriate dressings. Results: All injuries responded positively to photobiomodulation therapy and showed a rapid resolution of inflammation. Complete wound resolution was achieved in 11 of 12 cases. The average healing time was 3.7 days. Four injuries achieved resolution with only one application of blue light. Scores from the pain perception scales showed that the blue light treatment was well tolerated by pediatric patients, showing high parental compliance. No side effects or adverse events were observed. Conclusions: Blue light photobiomodulation proved to be a safe, well-tolerated, and effective technology in the treatment of pediatric skin injuries, with good acceptance by young patients and families. More structured clinical trials would be needed to validate the efficacy of blue light in pediatric injuries.